Clarification about using Angiotensin – receptor Blockers (ARBs)
2011-07-19
Further to the previous communication on SFDA website dated 7 Shaban 1432H (8 July 2011) regarding the news published on some newspapers related to safety and security issues of using Angiotensin – receptor Blockers (ARBs) and its relation with the risk of developing cancer, where ARBs are used to control high blood pressure, heart failure and diabetic kidney disorders ( click here to view ARBs registered in the Kingdom)